Clinical Trial Update: ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial assessing WSD0628, an ATM inhibitor, in combination with radiation therapy for recurrent high-grade glioma (glioblastoma) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• WSD0628 (ATM inhibitor)

Snippet

Sponsor: Mayo Clinic | Conditions: Glioblastoma | Phase 1 | Status: RECRUITING